Home » Stocks » CYTH

Cyclo Therapeutics, Inc. (CYTH)

Stock Price: $6.15 USD 0.01 (0.16%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $6.25 +0.10 (1.63%) Jan 22, 6:50 PM
Market Cap 28.69M
Revenue (ttm) 985,153
Net Income (ttm) -8.90M
Shares Out 1.52M
EPS (ttm) -7.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $6.15
Previous Close $6.14
Change ($) 0.01
Change (%) 0.16%
Day's Open 6.05
Day's Range 6.02 - 6.32
Day's Volume 208,905
52-Week Range 3.85 - 6.39

News

There are no news available yet.

About CYTH

Cyclo Therapeutics, a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo ... [Read more...]

Industry
Biotechnology
Founded
1990
CEO
N. Scott Fine
Employees
5
Stock Exchange
NASDAQ
Ticker Symbol
CYTH
Full Company Profile

Financial Performance

In 2019, CYTH's revenue was $1.01 million, a decrease of -0.42% compared to the previous year's $1.01 million. Losses were -$7.53 million, 77.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CYTH stock is "Buy" and the 12-month stock price forecast is 12.00.

Price Target
$12.00
Analyst Consensus: Buy